Data from multiple sources - Curated by Toby Galbraith - Last updated 06 June 2017

Cancer of prostate

Prostate cancer is one of the most commonly diagnosed cancer in males globally. It is a highly heterogeneous condition; it can be aggressive but will more typically develop


Read more on Cancer of prostate



Latest news articles

Added 4 days ago Drug news

CHMP recommends approval of Tookad (padeliporfin) for adenocarcinoma of the prostate.- STEBA Biotech.

The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation...

Added 5 days ago Drug news

Independent data monitoring committee determines that Phase III study of Prostvac in prostate cancer should not continue.- Bavarian Nordic.

Bavarian Nordic A/S announced that an independent Data Monitoring Committee (DMCB) has determined, based on a preplanned interim analysis, that...

Added 6 days ago Drug news

Phase III PROSPER trial of Xtandi (enzalutamide) plus androgen deprivation therapy (ADT) versus ADT alone for non-metastatic castration-resistant prostate cancer met its primary endpoint of improved metastasis-free survival.- Pfizer + Astellas

Pfizer Inc.and Astellas Pharma Inc. have announced that the Phase III PROSPER trial evaluating Xtandi (enzalutamide) plus androgen deprivation therapy...

Search all news articles for Cancer of prostate

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Breakthrough Cancer Pain Learning Zone

Invitation to watch the online broadcast of the BeCOn OWN event 'Shifting paradigms in BTcP management' on June 16 2017.

Visit Breakthrough Cancer Pain Learning Zone

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 1 more

Visit Prostate Cancer


EAU Guidelines on Prostate Cancer

The European Association of Urology (EAU) Guidelines Group for Prostate Cancer have prepared this guidelines document to assist medical professionals...

Added 1 year ago

Evidence-based indications for the use of PET-CT in the United Kingdom 2016

Since its introduction into clinical practice in the UK 26 years ago, positorn emission tomography (PET) followed by positron emission tomography-computed tomography...

Added 9 months ago

Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...

Added 2 years ago

Search all guidelines for Cancer of prostate

Journal articles

Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer.

Background: Abiraterone acetate, a drug that blocks endogenous androgen synthesis, plus prednisone is indicated for metastatic castration-resistant prostate cancer.

Added 6 days ago

Abiraterone for prostate cancer not previously treated with hormone therapy

Abiraterone acetate plus prednisolone improves survival in men with relapsed prostate cancer.

Added 2 months ago

Emotional distress increases the likelihood of undergoing surgery among men with localized prostate cancer

We determined whether among men with clinically localized prostate cancer, particularly men with low risk disease, greater emotional distress increases the likelihood of undergoing surgery vs radiation or active surveillance.

Added 3 months ago

Search all journal articles for Cancer of prostate

Clinical trials

Study of abiraterone acetate plus ADT versus apalatumide versus abiraterone and apalatumide in patients with advanced prostate cancer with non-castrate testosterone levels

Evaluation of the activity, safety and patients reported outcome of ADT plus abiraterone, abiraterone plus APALUTAMIDE (a second-generation antiandrogen) or APALUTAMIDE alone in hormone naïve locally advanced...

Added 11 months ago

Olaparib with or without cediranib in treating patients with metastatic hormone-resistant prostate cancer

This randomized phase II trial studies how well olaparib with or without cediranib works in treating patients with hormone-resistant prostate cancer that has spread to other places in the body.

Added 11 months ago

Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer

PART I - Hormone therapy with or without definitive radiotherapy in metastatic prostate cancer
The goal of this clinical study PART I is to determine impact of radiotherapy treatment in combination with...

Added 11 months ago

Search all clinical trials for Cancer of prostate
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.


Managing the side effects of treatment for prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
Registration required
Subscription fee

Managing patients at risk of prostate cancer

Accrediting body
BMJ Learning - British Medical Learning
Credits available
Registration required
Subscription fee

Guidance update: latest NICE guidelines on prostate cancer

Accrediting body
MIMS Learning - Monthly Index of Medical Specialities
Credits available
Registration required
Subscription fee
Search all CME for Cancer of prostate